Dermatix
PreclinicalSmall molecule
Dermatix is one of 34 small molecule programs targeting MPA. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
52 competitors in MPA
#DrugCompanyPhaseTrials
1Flomax
SanofiApproved
Repatha
AmgenApproved
Myrbetriq
AstellasApproved
Tremfya
Johnson & JohnsonApproved
Jardiance
Boehringer IngelheimApproved
Rituxan
RochePhase 3
Activella
Eli LillyPhase 3
Epsom Salt
FFresenius Kabi USA, LLC
Phase 3
Nitrostat
VViatris Specialty LLC
Phase 2
Obicetrapib
NNewAmsterdam Pharma
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dermatix. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity Hospital, Ghent